Takeda Pharmaceutical
390 hedge funds and large institutions have $3.65B invested in Takeda Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 308 funds opening new positions, 62 increasing their positions, 14 reducing their positions, and 9 closing their positions.
3,322% more first-time investments, than exits
New positions opened: 308 | Existing positions closed: 9
1,500% more funds holding in top 10
Funds holding in top 10: 1 → 16 (+15)
343% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 14
319% more funds holding
Funds holding: 93 → 390 (+297)
299% more capital invested
Capital invested by funds: $914M → $3.65B (+$2.73B)
4.01% more ownership
Funds ownership: 1.73% → 5.74% (+4%)
1% less call options, than puts
Call options by funds: $94.4M | Put options by funds: $95.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$525M |
| 2 |
PC
Paulson & Co
New York
|
+$267M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$215M |
| 4 |
AC
Adelphi Capital
London,
United Kingdom
|
+$187M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$200M |
| 2 |
Citigroup
New York
|
-$127M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$90.5M |
| 4 |
Goldman Sachs
New York
|
-$47.1M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$23.5M |
TAK Hedge Fund Activity: Q1 2019 in Review
390 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2019, worth a combined $3.65B — up 299% from $914M a quarter earlier.
Buyers outnumbered sellers: 308 funds opened new TAK positions and 9 closed out — a net gain of 299 holders — while 62 added to existing stakes and 14 trimmed.
The largest buyer was Glenview Capital Management, opening a new position worth an estimated $525M. The largest seller was UBS Group, cutting an estimated $200M.
- 390 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2019, up from 93 in Q4 2018.
- Funds reported $3.65B of Takeda Pharmaceutical stock for Q1 2019, up 299% quarter-over-quarter.
- 308 funds opened new Takeda Pharmaceutical positions in Q1 2019 and 9 closed out, a net change of +299 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2019 was Glenview Capital Management, an estimated $525M added.
- The largest Takeda Pharmaceutical seller in Q1 2019 was UBS Group, an estimated $200M sold.
Based on aggregated 13F filings for Q1 2019.